NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/20/2026
Back to search
Official data from USPTO
PRENOSTIC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PRENOSTIC
ST13
US500000098628856Class
1, 5, 10, 42, 44
Filing
98628856
Registration
8106198
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 10, 42, 44
Filing date
07/02/2024
Registration date
01/20/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/20/2026
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
OXFORDSHIRE, ENGLAND,, GB
Examiner
RUIZ SANTIAGO, REBECCA E
Law office
O30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
PRENOSTICS LIMITED
RNA GUARDIAN LTD
Representatives
Ben Natter Haug Partners, LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
In-vivo diagnostic reagents for scientific use; Diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; Diagnostic reagents for scientific or research use; all of the aforesaid services provided in relation to cancer diagnosistreatment and therapy
Class 5
Medical diagnostic reagents; Clinical medical diagnostic reagents; Reagents for use in diagnostic tests for medical purposes; Medical diagnostic reagents and assays for testing of body fluids; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical use; Reagents and media for medical and veterinary diagnostic purposes; Diagnostic testing materials being diagnostic reagents for medical use; Chemical diagnostic reagents for medical use; Diagnostic chemical reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Indicators for medical diagnosismedical diagnostic reagents; Reagents for use in medical genetic testing; Diagnostic preparations for medical purposes; Diagnostic reagents for medicinal use; Reagents for use with analyzers for medical use; Diagnostic agents for medical use; Radio-isotope markers for therapeutic or diagnostic use; Biopharmaceuticals preparations for the treatment of cancer; Compounds for treating cancerliquid compounds for medical or therapeutic use; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for the treatment of tumours; Pharmaceutical preparations for the prevention of tumours; Anti-cancer drugs being pharmaceutical preparations for the prevention of cancer; Chemotherapeutics; Pharmaceutical preparations for the treatment of diseases of the metabolic system; Pharmaceutical preparations for suppressing tumors; Tumor suppressing agents; Protein synthesis inhibitorspharmaceutical substances for slowing cell growth for medical purposes; Neoantigensantibody reagents used for the detection of antigens in cells and tissue for medical purposes; Diagnostic radiopharmaceutical preparations; Clinical medical reagents; all of the aforesaid services provided in relation to cancer diagnosistreatment and therapy
Class 10
Tools for medical diagnosticsMRI apparatus for medical purposesX-ray CT scannersBiopsy instruments; Diagnostic testing instruments for use in immunoassay procedure for medical diagnosis purposes; Testing probes for medical diagnostic purposes; Diagnosticexaminationmonitoring equipmentMRI apparatus for medical purposesX-ray CT scannersBiopsy instruments; Medical diagnostic testing apparatus for use in immunoassay procedures; Medical diagnostic instrumentsBiopsy instruments; Testing instruments for medical diagnostic purposesMRI apparatus for medical purposesX-ray CT scannersBiopsy instruments; Nuclear medicine diagnostic imaging apparatus; Spectrum analyzers in the nature of cancer and pre-cancerous cells and RNA and DNA analysis for use in medical diagnosis; Diagnostic imaging apparatus for medical use; Diagnostic instruments for medical use; Diagnostic apparatus for cancer and pre-cancerous cells and RNA and DNA analysis for medical purposes; Medical diagnostic apparatus cancer and pre-cancerous cells and RNA and DNA analysis for medical purposes; Medical apparatus for the treatment of cancer; Medical apparatus for tumour diagnosis; all of the aforesaid services provided in relation to cancer diagnosistreatment and therapy
Class 42
Product design and development of medical technology; Computer diagnostic services; Product development of medical diagnostic apparatus; Research and development in the field of diagnostic preparations for medical purposes; Scientific and technological servicesresearch and design in the field of cancerpre-cancerous cellsRNA and DNA analysis; ; industrial analysis in the nature of cancerpre-cancerous cellsRNA and DNA analysis and product research services; design and development of computer hardware and software; design and development of computer hardware and softwarein particular computer programs; scientific research for medical purposesin particular research and development in the field of human medical and veterinary medical diagnostics and therapy; Medical research; Scientific research for medical purposes in the field of cancerpre-cancerous cellsRNA and DNA analysis; Scientific research for medical purposes in the area of cancerous diseases; Advice on scientific information relating to alleviationdiagnosisprevention and treatment of cancer; Administration of researchscientific research in the fields of healthdietnutritioncancer and cancer prevention; Biologicalscientific and oncological research laboratories services; Preparation of biological samples for testing and analysis in research laboratoriesresearch services in the field of forensic science in the nature of analysisdetection and isolation of biological substances in forensic samples; Provision of information and data relating to medical and veterinary research and development; all of the aforesaid services provided in relation to cancer diagnosistreatment and therapy
Class 44
Medical diagnostic services; Medical testing for diagnostic or treatment purposes; Medical analysis services for the diagnosis of cancer; Remote monitoring of medical data for medical diagnosis and treatment; Medical analysis services for cancer diagnosis and prognosis; Medical testing services relating to the diagnosis and treatment of disease; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Performing diagnosis of diseases; Prostate cancer screening services; Breast cancer screening services; Lung cancer screening services; Testicular cancer screening services; Cervical cancer screening services; Bowel cancer screening; all of the aforesaid services provided in relation to cancer diagnosistreatment and therapy
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/20/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2025
PUBO
PUBLISHED FOR OPPOSITION
12/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/26/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/04/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
11/04/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/04/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
11/04/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/04/2025
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/12/2025
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/05/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/05/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/24/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/06/2025
GNRT
NON-FINAL ACTION E-MAILED
02/06/2025
CNRT
NON-FINAL ACTION WRITTEN
02/06/2025
DOCK
ASSIGNED TO EXAMINER
01/21/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/14/2025
NWAP
NEW APPLICATION ENTERED
07/02/2024
Continuous trademark protection
Get notified about every new filing that threatens PRENOSTIC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.